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Abstract 
Decreases in cortical volume (CV), thickness (CT) and surface area (SA) have been reported 
in individuals with schizophrenia by in vivo MRI studies. However, there are few studies that 
examine these cortical measures as potential biomarkers of treatment resistance (TR) and 
treatment response (NTR) in schizophrenia. This study used structural MRI to examine 
differences in CV, CT, and SA in 42 adults with schizophrenia (TR=21, NTR=21) and 23 
healthy controls (HC) to test the hypothesis that individuals with TR schizophrenia have 
significantly greater reductions in these cortical measures compared to individuals with NTR 
schizophrenia. We found that individuals with TR schizophrenia showed significant reductions 
in CV and CT compared to individuals with NTR schizophrenia in right frontal and precentral 
regions, right parietal and occipital cortex, left temporal cortex and bilateral cingulate cortex. 
In line with previous literature, the temporal lobe and cingulate gyrus in both patient groups 
showed significant reductions of all three measures when compared to healthy controls. Taken 
together these results suggest that regional changes in CV and CT may index mechanisms 
specific to TR schizophrenia and potentially identify patients with TR schizophrenia for earlier 
treatment.  
 
KEY WORDS: Schizophrenia, Treatment Resistant, Cortical Thickness, MRI, Cortical 
Volume 
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1. Introduction 
Schizophrenia is a psychiatric disorder characterized by symptoms such as hallucinations, 
paranoia, and delusions. As such, schizophrenia is often associated with life-long disability, 
increased risk of mortality, significant social and economic cost due to long-term 
unemployment (Velligan et al., 2009). Delays in seeking and identifying effective treatment 
following the onset of schizophrenia is correlated with illness duration, loss of social and 
occupational function, and increase in treatment resistance (Elkis and Buckley, 2016; Harvey 
and Rosenthal, 2016). Contemporary first-line antipsychotic medications such as olanzapine, 
risperidone and haloperidol have shown significant efficacy in treating schizophrenia, 
predominantly through the blockade of dopaminergic (D2) receptors (Bodén et al., 2017; 
Goghari et al., 2010; Jørgensen et al., 2016). Despite the widespread use of dopaminergic 
agents, approximately one third of patients with schizophrenia demonstrate resistance to 
traditional anti-psychotic treatments, suggesting an alternative mechanism of action may 
underlie symptoms in these individuals (Elkis and Buckley, 2016; Harvey and Rosenthal, 2016; 
Nakajima et al., 2015). Clozapine remains the most viable treatment for such patients. 
However, clozapine is associated with severe side effects resulting in poor patient tolerance 
and adherence (Chakos et al., 2001). 
Theories proposed to explain resistance to first line anti-psychotics include the continuum 
perspective, suggesting that treatment resistant schizophrenia (TR) is a more severe form of 
schizophrenia, and the heterogeneity theory, suggesting TR is a separate and categorically 
different form of illness underpinned by a different neuropathological mechanism. Current 
evidence suggests that delays in seeking treatment is correlated with poor outcome, which may 
support a third neurodegenerative theory suggesting that TR can be induced and worsened by 
increased environmental insults and lack of effective treatment (Howes and Kapur, 2014; 
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Szeszko et al., 2012; van Haren et al., 2008). However, a likely explanation of TR in patients 
with schizophrenia may include more than one of these aforementioned theories, which may 
overlap and predispose patients to a TR trajectory. 
Understanding how these theoretical approaches to schizophrenia relate to the neurobiological 
mechanisms underlying TR is important to the development of novel treatment approaches to 
TR patients and improving diagnostic approaches to first episode psychosis. Differences in 
brain structure and function in TR patients relative to those who respond to first line 
dopaminergic agents (NTR) indicates the possibility of these measures being developed into 
imaging biomarkers to identify patients at risk of resistance to first-line treatment, and those 
suitable for earlier clozapine treatment. Investigation into neurobiological changes which are 
associated with aspects of schizophrenia that are specific to TR may be used reliably to identify 
TR and potentially clinically reduce risk associated with delays in efficient treatment. 
Neuroimaging studies using high resolution MRI (Magnetic Resonance Imaging) demonstrate 
widespread differences in patients with schizophrenia in cortical grey matter volume (CV) 
(Anderson et al., 2015; Molina et al., 2010, 2008, 2005; Mouchlianitis et al., 2016; Zugman et 
al., 2013) cortical thickness (CT) (Heinrichs et al., 2017; Kuperberg et al., 2003; Narr et al., 
2005; Nesvåg et al., 2008; Plitman et al., 2016; Rimol et al., 2010; Smiley et al., 2012; Sugihara 
et al., 2017) and surface area (SA) (Kong et al., 2015; van Haren et al., 2012; Xiao et al., 2015) 
compared to healthy controls (HC) (Maller et al., 2012; Quarantelli et al., 2014; Selemon and 
Goldman-Rakic, 1999). CV reductions in patients with schizophrenia are one of the most 
common findings in the condition, beginning with global grey matter reductions and associated 
increases in ventricular volume (Emami et al., 2016; Harvey et al., 1993; Honea et al., 2005; 
Kong et al., 2015; Shergill et al., 2001). Further studies have highlighted the importance of 
investigating CT and SA in addition to CV alone as each of these component measures has 
been shown to represent unique aspects of cortical architecture (Rakic, 1995) with different 
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aetiologies, genetic determinants (Nesvåg et al., 2008; Panizzon et al., 2009) and 
neurodevelopmental trajectories (Ecker et al., 2014). CT has been shown to be influenced by a 
number of neuro-developmental factors including neuronal size, intra-neuronal neuropil, 
number of glial cells and blood vessels (Rakic, 1995). SA expansion has been attributed to the 
proliferation of cortical neuronal columns (Crespo-Facorro et al., 2000; Rakic, 1995). Thus, 
determining which of these measures procures  CV differences in TR could contribute to 
understanding the underlying pathogenesis of TR and the effects that antipsychotics have on 
cortical morphology.  However, in previous research few studies explored the relationship 
between cortical measures and treatment response directly.  
Longitudinal assessment of CT and SA has demonstrated significant degeneration of frontal, 
temporal and parietal grey matter over time in patients with schizophrenia (van Haren et al., 
2012). Furthermore, significant decreases in CT in the temporal lobe and in CV and CT of the 
dorso-lateral prefrontal cortex (dlPFC) have been noted in TR compared to NTR schizophrenia 
(Zugman et al., 2013). In addition, CT in the temporal lobe has been associated with treatment 
response and remission (Szeszko et al., 2012). Based on these reports, a link between temporal 
lobe CT and persistence of symptoms such as auditory hallucination or the failure of the 
mechanism identifying such hallucinations as internally generated has been proposed (Emami 
et al., 2016; Rimol et al., 2010; Shergill et al., 2001). Taken together, these results indicate that 
cortical surface measures in both the frontal and the temporal lobe may be an indicator of 
treatment resistance in schizophrenia patients. Therefore, this study aims to explore the 
differences in these cortical measures between TR and NTR patients and HC to establish 
whether there are specific cortical indicators of schizophrenia and different cortical indicators 
of TR.  
In order to limit confounding variables in our patient groups, crucially, we controlled for 
potential influences on cortical measures such as age, medication dosage, illness onset and 
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duration, and we recruited only patients who are not treated with clozapine. These exclusion 
criteria allowed us to maintain the homogeneity of the populations sample while continuing to 
meet the criteria for TR. To our knowledge this is the first study of cortical morphology to 
stratify a sample in this way. We test the hypotheses that i) we will see a decrease in CV, CT 
and SA in all patients compared to HC, ii) TR patients will exhibit CV, CT and SA reductions 
in the frontal and temporal lobes compared to NTR and iii) the extent of these cortical changes 
will positively correlate with symptom scores in the TR group. By identifying differences in 
cortical structure between TR and NTR patient groups we aim to identify neuroanatomical 
features to further the understanding, identification and stratification of TR schizophrenia.  
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2. Methods  
2.1 Subjects 
We recruited 42 patients who satisfied ICD-10 1992 criteria for schizophrenia from the South 
London and Maudsley (SLaM) National Health Service (NHS) and 23 HC within the same 
range of age, sex, and socioeconomic status. The patient population was stratified into TR 
(n=21) and NTR (n=21) groups. The criteria for inclusion in the TR group included: at least 
two prior drug trials of 4-6 weeks duration with no clinical improvement and persistent 
psychotic symptoms as defined as a score of at least 4 (moderate) on at least two positive 
symptom items of the Positive and Negative Syndrome Scale, PANSS (Kay et al., 1989), with 
a duration of over 5 years. Patients in the NTR group were defined by a score of 3 or less (stable 
for at least 6 months) on all items of the PANSS (Andreasen et al., 2005; Conley and Kelly, 
2001). No patients had been on clozapine in the last 6 months. IQ was measured with the two-
item Wechsler Abbreviated Scale of Intelligence, WASI (Weschler, 2008). Chlorpromazine 
(CPZ) equivalent doses of medications were calculated using conversion tables (Bazire, 2016; 
Woods, 2003). Further demographics and clinical data are presented in Table 1.  
 
2.2 Procedure  
2.2.1. Magnetic Resonance Imaging 
MRI was performed using a General Electric MR750 3T scanner. A T1-weighted spoiled 
gradient three-dimensional magnetization prepared rapid acquisition was used to acquire high-
resolution structural images of the brain (repetition time, 7.312ms; echo time, 3.016ms; flip 
angle 11°; matrix size 256x256; field of view, 270) with 196 sagittal positions (at 1.2 x 1.05 x 
1.05mm resolution). 
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2.2.2. Cortical Reconstruction with FreeSurfer 
Cortical surface reconstruction of each subject’s T1-weighted volumetric images was 
performed using FreeSurfer 5.2.0 (freesurfer.net). This resulted in a white matter and outer pial 
(i.e. grey matter) surface mesh for each subject (Dale et al., 1999; Fischl et al., 1999; Fischl 
and Dale, 2000; Jovicich et al., 2006; Ségonne et al., 2004). All surfaces were visually 
inspected for errors in reconstruction in comparison to the underlying T1-weighted image in 
line with standardised QA protocols (Dale et al., 1999; Jovicich et al., 2006; Ségonne et al., 
2004). Subjects with poor quality reconstructions were subsequently removed and are not 
described in this study (TR=1, NTR=1). In addition to vertex-wise measures of CV, CT was 
estimated as the distance between corresponding vertices on the white matter and outer grey 
matter (i.e. pial) surface (Dale et al., 1999). Vertex-wise estimates of SA were also derived on 
the grey matter surface using a pycnophylactic or mass preserving interpolation method (Dale 
et al., 1999). Prior to any further statistical analysis each measure was smoothed using a 10mm 
FWHM surface based Gaussian kernel. 
 
2.2.3. Statistical Analysis of Cortical Measures 
To assess the relationship between vertex-wise measures of CV, CT, SA, and clinical measures 
of interest, we used a general linear model (GLM) based multiple regression approach with 
diagnostic group and sex as fixed-effect factors and age, IQ, total PANSS score, and medication 
dose as continuous co-variates: 
 
Yi = β0 + β1Group + β2Sex + β3Age + β4IQ + β5PANSS + β6Meds + εi, 
 
where εi is the residual error at vertex i.  Between group differences were estimated from the 
corresponding coefficient β1, normalised by the corresponding standard error. Corrections for 
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multiple comparisons across the whole brain were performed using random field theory 
(RFT) based cluster analysis using a cluster-based significance threshold of p< 0.05 (2-tailed 
(Hayasaka et al., 2004; Winkler et al., 2012; Worsley et al., 2004). Differences in global 
measures of CV, CT, and SA between HC, TR, and NTR patient groups were assayed with a 
one-way ANOVA and followed up with pairwise independent samples t-tests (2-tailed). 
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3. Results 
We observed no significant differences in age, IQ, medication dose, illness onset, and illness 
duration between patient groups (p<0.05) but found a significant difference in IQ in patients 
compared to HC (Table1). 
3.1 Global measures 
A one-way ANOVA was conducted to find the effect of group on CV, CT, and SA. A 
significant decrease was observed when comparing HC, TR, and NTR groups in a linear trend 
indicating HC>NTR>TR, on global mean CV (F(2,62)= 6.22, p= .003), CT (F(2,62)= 3.38, p= 
.04), and near significant in SA measures (F(2,62)= 3.03, p=. 056) (Figure 1). These differences 
could not be explained by group differences in total intracranial volume (ICV) (F(2,62)= 1.47, 
p= .237) (Figure 1). A post hoc comparison revealed: 
i) Significant CV reductions (p= .005, Bonferroni corrected) in TR (M=4.89x105, 
SD=4.78x104) and NTR patients (M=5.01x105, SD=7.45x104) compared to HC 
(M=5.54x105, SD=4.76x104) (Figure 1)  
ii)  Significant reduction in mean CT (p= .046, Bonferroni corrected) in TR patients 
(M=2.79, SD=.22) and but not NTR patients (M=2.83, SD=.26) compared to HC 
(M=2.93, SD=.08) (Figure 1).  
iii) No significant decrease in mean SA in NTR (M=9.87x104, SD=1.03x104) or TR 
patients (M=9.72x104, SD=7.21x103) compared to HC (M=1.04x105, 
SD=.9.24x103) (Figure 1). 
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3.2 Differences in cortical volume, cortical thickness and cortical surface area associated 
with schizophrenia  
Vertex-wise analyses showed significant decreases in CV in the patient group compared to HC 
in seven clusters centred on the right insula (t= -4.07, p< .001), left insula (t= -3.31, p< .001), 
left inferior temporal (t= -5.51, p< .001) right lateral occipital (t= -4.54, p< .001), left precuneus 
(t= -4.00, p< .001), right middle temporal gyrus (t= -3.16, p< .05) and right precuneus (t= -
4.04, p< .05) (Table 2). We observed decreases in CT in patients with schizophrenia compared 
to HC in two clusters centred on the right superior temporal gyrus (STG) (t= -3.48, p< .001) 
and left inferior temporal gyrus (t= -3.61, p< .05) (Table 2). There were significant decreases 
in SA in patients compared to HC in five clusters centred on the left precuneus (t= -4.00, p< 
.001), right precentral gyrus (t= -3.33, p< .001), left inferior temporal gyrus (t= -5.01, p< .05), 
right STG (t= -3.84, p< .05), and right medial orbital frontal cortex (t= -3.59, p< .05) (Table 2, 
Figure 2).  
Mean cluster values across groups are visualised in Figure 3. Although there were no 
significant correlations between PANSS symptom scores and significant cortical clusters there 
was a group trend indicating that PANSS negative scores were related to significant cortical 
clusters in NTR patients (see Supplemental Materials for details). 
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3.3 Differences in cortical volume, cortical thickness and cortical surface area associated 
with treatment resistance  
Significant decreases in CV were found in TR patients compared to NTR patients in one cluster 
incorporating the right frontal and precentral regions (t= -4.43, p< .05). Similarly, significant 
decreases in CT were also found in TR patients compared to NTR patients in four clusters 
including the right parietal and occipital regions (t= -2.92, p< .001), left temporal regions (t= -
3.65, p< .05), right isthmus cingulate regions (t= -4.11, p< .05), and left isthmus cingulate 
regions (t= -3.65, p< .05) (Table 3). In contrast, an increase in SA in TR patients compared to 
NTR patients was observed in one cluster incorporating the right postcentral gyrus and superior 
parietal cortex (t= 3.47, p< .05) (Table 3, Figure 3). There were no significant correlations 
between significant cortical clusters and PANSS scores in the TR patient group. However, a 
group trend showing a negative correlation between negative symptoms and cortical measures 
in the NTR patient group was observed (see Supplemental Materials).  
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4. Discussion 
In this study we examined differences in measures of cortical morphology between two groups 
of patients with TR and NTR schizophrenia, and HC. In order to demonstrate differences in 
cortical measures specific to schizophrenia we compared the entire patient group with HC on 
all cortical measures and found significant reductions in measures of CV, CT, and SA in 
patients with schizophrenia compared to HC. Examination of independent patient groups (TR 
vs NTR) revealed that individuals with TR schizophrenia where found to have more severe 
reductions in CV and CT across areas of the temporal and frontal lobes, in line with previous 
reports in this population. However, these results also showed an increase in SA in the superior 
parietal and postcentral gyrus, contrary to previous research (Kong et al., 2015; Rimol et al., 
2012). Taken together it could be proposed that CT reductions may play a significant role in 
CV reductions in schizophrenia. While further research with a larger sample size is required, 
these preliminary results could indicate the existence of a neurobiological mechanism specific 
to CT that is influencing treatment response.  
We also observed significant CV and CT reductions in TR compared to NTR patients in regions 
previously reported as atypical in schizophrenia, including the inferior parietal, lateral occipital 
cortex, superior temporal sulcus, and lingual and superior temporal gyrus (Nesvåg et al., 2008; 
Rimol et al., 2010; Szeszko et al., 2012). CV reductions in patients with schizophrenia are one 
of the most common findings in the condition, beginning with global grey matter reductions 
characterized by an increase in ventricular volume (Harvey et al., 1993; Honea et al., 2005; 
Kong et al., 2015; Shergill et al., 2001).  The few studies that have compared TR and NTR 
patients with schizophrenia have found specific CV decreases in the dorso-lateral prefrontal 
cortex, temporal regions (Rimol et al., 2012), putamen and caudate nucleus (Molina et al., 
2010).  
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In addition to CV, the current study examined CT and SA measures in TR schizophrenia as 
earlier work has highlighted each of these component measures to represent unique aspects of 
cortical architecture (Rakic, 1995) with different aetiologies, genetic determinants (Nesvåg et 
al., 2008; Panizzon et al., 2009) and neurodevelopmental trajectories (Ecker et al., 2014; Hyde 
et al., 2010). Brain regions found to have decreased CT among schizophrenia patients in this 
study have been previously indicated across several stages of the disease/condition including; 
ultra-high risk, first episode psychosis, and chronic schizophrenia (Narr et al., 2005; Plitman 
et al., 2016; Xiao et al., 2015). Therefore, it has been suggested that reduced CT could be a 
potential risk factor for schizophrenia and thus may have potential to act as marker of TR 
(Hedman et al., 2016; Narr et al., 2005; Plitman et al., 2016; Xiao et al., 2015). 
There also appeared to be a distinction in regions of CT reductions in TR patients. In agreement 
with previous literature, this study found significant CT reductions in TR patients in the 
temporal cortex of the left hemisphere (Cui et al., 2018; Rimol et al., 2010). This lateralisation 
of reductions in temporal CT may be an important part of treatment response and 
symptomatology as it is estimated up to 95% of language process occurs laterally in the left 
hemisphere (Barrick et al., 2005; Geschwind and Levitsky, 1968). Previous research has 
suggested that the left hemisphere has a dominant role in language processing in HC and it has 
been suggested that this lateralisation may be dysfunctional or disrupted in schizophrenia 
(Barrick et al., 2005; Geschwind and Levitsky, 1968). This disruption has been suggested to 
contribute to auditory hallucinations and language conceptual disorganisation symptoms in 
patients with schizophrenia (Shenton et al., 1992). The superior temporal sulcus and middle 
temporal gyrus in particular have been consistently found to be associated with auditory 
hallucinations in both structural and functional imaging studies (Cui et al., 2018; Shergill et al., 
2004, 2003, 2001).  
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In contrast to previous literature, which has reported no differences or reductions in SA 
(Szeszko et al., 2012), our data showed an increase in SA in the right postcentral and superior 
parietal gyrus in TR patients. The parietal lobe has been suggested to be crucial to social 
cognition, agency and biological motion (Frith et al., 2000; Iacoboni and Dapretto, 2006; Kato 
et al., 2011). Over-activation of the parietal cortex has been associated with delusions of 
control, where patients are unable to recognise internal and external biological motion (Kato et 
al., 2011). Guo and colleagues (Guo et al., 2014) found that a consistent disruption of the 
medial and mirror neuron system was associated with sensory and cognitive functions, 
particularly self-processing and agency, over varied illness duration. One could speculate the 
increase in SA in the superior parietal gyrus in the TR patient group could reflect an over-
activation in this region, although this should be interpreted with caution due to the 
correlational nature and the relatively small sample size in this study.  
Previous studies of cortical measures in patients with schizophrenia have included patients 
treated with clozapine and reported prefrontal cortical atrophy in individuals with a poor 
response to this treatment (Chiappelli et al., 2017). This study investigated the TR 
schizophrenia population while controlling for potential confounding effects by excluding 
patients with schizophrenia who were on or had been on clozapine. This exclusion criterion 
allowed for the homogeneity of the patient sample to be maintained while still meeting the 
criteria for TR. However, while CV and CT reduction was observed at this late stage of illness, 
due to the chronicity of the illness these results could be confounded by several factors. While 
this study found no significant differences across patient groups in age, illness duration, illness 
onset, medication dose and intra-cranial volume (ICV), cumulative medication over the 
lifespan may be a significant factor affecting CV and CT which assumedly would be higher in 
TR compared to NTR patients (Harrison et al., 2003). Indeed, while medication type and dose 
were accounted for in this study, medication adherence and its influence on the treatment 
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response of both groups remains unqualified. In addition, this study mainly included males 
with schizophrenia and cortical surface measures may differ in the female population. The 
genesis of these cortical decreases can only be speculated from this patient population as data 
was collected at a singular time point and thus future longitudinal studies should be required to 
follow up participants at a number of time points and begin participation in the study when 
patients are medication-free. In addition this chronic population could have been exposed to 
earlier comorbidities such as depression or mood disorders and secondary illnesses such as 
substance abuse and prolonged stress, which may have impacted the underlying brain 
pathology (Heinrichs et al., 2017; Konopaske et al., 2007). Recent studies have suggested that 
stress could contribute to an increased rate of cortical thinning, which should be considered 
when discussing patients with chronic schizophrenia (Harrison, 1999; Konopaske et al., 2007). 
While these various factors make it difficult to fully characterize cortical differences between 
TR and NTR patients, there is no reason to conclude that these factors would differentially 
impact TR versus NTR patients.  
 
In summary, this study demonstrated that TR patients with schizophrenia show specific and 
significant reductions in CT and CV and increases in SA compared to NTR patients. These 
cortical differences were located in regions of particular interest to schizophrenia in the 
temporal, parietal and medial regions (Rimol et al., 2012; Shergill et al., 2001). Since CT 
reductions have been reported at all stages of schizophrenia, further research should be 
conducted to determine the nature of the relationship between CT, schizophrenia illness onset 
and trajectory. While the causal impact of these cortical changes remains elusive, it can be 
speculated that a deficit in CT may make an organism more intolerant to insult and therefore 
predispose the organism to neurological insult or illness outbreak. These cortical measures may 
reflect mechanisms underlying aspects of neurological disorganisation and pathology in many 
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respects. Future studies require longitudinal scans at several time points to determine reliable 
pathological trajectories, and larger sample sizes are needed to confidently show generalizable 
effects.  
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Tables 
Table 1. Demographics and clinical data including the Weschler abbreviated scale of 
intelligence (WASI), National Statistic for Socio-economic Classification (NS-SEC), 
Chlorpromazine equivalent (CPZ) and Positive and Negative Symptom Scale (PANSS) 
expressed in means (M) and standard deviations (SD). 
 HC (N=23) NTR (N=21) TR (N=21) Group statistics 
 M SD M SD M SD χ2(2) P 
Female(Male) (%) 26(74)  14(86)  14(86)  1.18 .555 
         
       F(2,62) P 
Age 38.4 10.0 41.3 10.4 41.5 10.6 0.46 .641 
WASI IQ 115.8 11.7 91.86 14.8 97.1 16.4 16.8 <.001 
NS-SEC 3.13 1.62 3.74 1.88 3.39 1.76 0.65 .525 
         
       t(42) P 
Onset age (years)   27.7 6.2 26.0 7.7 -0.75 .431 
Illness duration 
(years) 
  14.1 10.1 15.5 8.8 0.46 .650 
CPZ equivalents 
(mg) 
  280.3 147.1 383.5 236.5 1.88 .067 
PANSS score         
  Positive    10.7 2.1 20.5 3.1 12.10 <.001 
  Negative    13.1 4.6 19.5 4.6 4.08 <.001 
  General    23.6 5.1 34.9 9.2 4.91 <.001 
Total score   46.9 10.3 76.2 10.6 9.14 <.001 
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Table 2. Clusters of significance (RFT, p< .05) between treatment resistant (Treatment Resistant) and non-treatment resistant (NTreatment 
Resistant) patients with schizophrenia.  Brodmann Area (BA), left(L), right(R), ‘Vertices’ indicates the number of vertices within the cluster, tmax 
represents the maximum t statistic within the cluster at the x y z Talairach coordinates reported, pcluster is the cluster corrected P value for 
significance reporting. 
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Table 3. Clusters of significant reduction (RFT, p< .05) between patients and HC on cortical 
surface measures. Brodmann Area (BA), left(L), right(R), ‘Vertices’ indicates the number of 
vertices within the cluster, tmax represents the maximum t statistic within the cluster at the x y 
z Talairach coordinates reported, pcluster is the cluster corrected P value for significance 
reporting. 
 
Measure Cluster Region Labels H BA  
(tmax) 
Vertices Talairach tmax Pcluster 
      
X Y Z 
  
Cortical 
Thickness 
Patients>HC 
1 Insula, precentral gyrus, superior 
temporal gyrus, supramarginal gyrus , 
transverse temporal cortex 
R 13 4764 33 7 12 -3.48 1.21x10-3 
 
2 fusiform gyrus, inferior temporal gyrus, 
middle temporal gyrus  
L 20 2586 -31 -38 -16 -3.61 1.05x10-2 
Cortical 
Volume 
Patients>HC 
1 Insula, lateral orbital frontal cortex, pars 
opercularis, postcentral gyrus, 
precentral gyrus, superior temporal 
gyrus, supramarginal gyrus , transverse 
temporal cortex 
R 44 14537 48 5 13 -4.07 7.95x10-6 
 
2 Insula, lateral orbital frontal cortex, 
medial orbital frontal cortex, pars 
opercularis, precentral gyrus, superior 
temporal gyrus 
L 11 6797 -6 44 -20 -3.31 1.93x10-5 
 
3 inferior temporal gyrus, middle 
temporal gyrus  
L 20 3423 -53 -22 -25 -5.51 5.74x10-4 
 
4 entorhinal cortex, fusiform gyrus, 
lateral occipital cortex, 
parahippocampal gyrus 
R 17 3789 21 -89 -2 -4.54 5.73x10-4 
 
5 isthmus-cingulate cortex, precuneus 
cortex  
L 30 4093 -5 -46 22 -4.00 1.67x10-3 
 
6 inferior temporal gyrus, middle 
temporal gyrus  
R 20 2270 53 -27 -16 -3.16 2.06x10-2 
 
7 isthmus-cingulate cortex, precuneus 
cortex  
R 23 2500 5 -46 22 -4.04 4.21x10-2 
Cortical Surface 
Area  
Patients>HC 
1 isthmus-cingulate cortex, precuneus 
cortex 
L 30 4207 -6 -47 20 -4.00 3.83x10-4 
 
2 pars opercularis, postcentral gyrus,  
precentral gyrus 
R 9 3646 49 4 21 -3.33 2.24x10-3 
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3 inferior temporal gyrus, middle 
temporal gyrus 
L 20 1806 -53 -23 -25 -5.08 6.50x10-3 
 
4 Superior temporal gyrus,  transverse 
temporal cortex 
R 22 2255 55 -7 -2 -3.84 9.92x10-3 
 
5 medial orbital frontal cortex, superior 
frontal cortex 
R 11 1541 10 50 -20 -3.59 2.84x10-2 
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Figure legends 
Figure 1. Trends in mean global measures across groups. Measures include estimated 
intracranial volume (ICV), mean cortical volume (CV), mean cortical thickness (CT), and mean 
pial surface area (SA) across groups including healthy controls (HC), treatment responsive 
(NTR), and treatment resistant (TR) patients with schizophrenia.  
Figure 2. Reduced cortical measure clusters for Treatment Resistant compared to Non-
Treatment Resistant. Regions of significantly reduced (RFT, p< .05) cortical thickness, cortical 
volume, and cortical surface area in individuals with Treatment Resistant schizophrenia 
compared to Non-Treatment Resistant schizophrenia. See Table 2 for further statistical cluster 
details. 
Figure 3. Reduced cortical measure clusters for patients compared to healthy controls. Regions 
of significantly reduced (RFT, p< .05) cortical thickness, cortical volume, and cortical surface 
area in individuals with schizophrenia compared to HC. Corrected t-maps see on the left and 
uncorrected t-maps seen on the right. See Table 3 for further statistical cluster details. 
 
 
 
